Flow chart for inclusion and exclusion criteria. by Maleda Tefera (9025154)

“…Conversely, the likelihood of wasting decreased in children breastfeeding in their second and third year of life (AOR: 0.75; 95% CI 0.67, 0.83) and (AOR: 0.50; 95% CI 0.43, 0.60) respectively. …”

Data_Sheet_1_Exploiting the microbiota of organic and inorganic acid-treated raw poultry products to improve shelf-life.docx by Dana K. Dittoe (10649702)

“…On d 14, those treated with SBS and SBS + PAA had lower relative abundance of typical spoilage population while having a greater relative abundance of Bacillus spp. (~70 and 50% of population; ANCOM p < 0.05). …”

TGFβ1 and unfolded protein response (UPR) in calreticulin expressing hearts. by Jody Groenendyk (3149277)

“…<p>(<b>A)</b> Immnoblot analysis and quantification of TGF-β1 protein in control and Heart^CRT+ hearts. …”

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney... by Rajiv Agarwal (12950)

“…Corresponding results in those not using a GLP-1 RA at baseline were −56% (−62 to −50), −37% (−45 to −28), and −33% (−41 to −23), respectively. …”

Presentation_1_The Successional Changes in the Gut Microbiome of Pasture-Raised Chickens Fed Soy-Containing and Soy-Free Diets.pdf by Jeferson M. Lourenco (6702122)

“…Results showed that at the phylum level, regardless of diet and birds' stage of life, there was a predominance of the phylum Firmicutes, which ranged from 50 to 90% of all OTUs in all samples. …”

Integrative Approach Detected Association between Genetic Variants of microRNA Binding Sites of TLRs Pathway Genes and OSCC Susceptibility in Chinese Han Population by Yun Wang (32846)

“…<div><p>Oral squamous cell carcinoma (OSCC) is a leading malignancy worldwide; the overall 5-year survival rate is approximately 50%. …”

The Native <em>Wolbachia</em> Endosymbionts of <em>Drosophila melanogaster</em> and <em>Culex quinquefasciatus</em> Increase Host Resistance to West Nile Virus Infection by Robert L. Glaser (244339)

“…<em>Wolbachia</em>-infected flies had a 500-fold higher ID₅₀ for WNV and produced 100,000-fold lower virus titers compared to flies lacking <em>Wolbachia</em>. …”

S1 Dataset - by Zhenyu Wang (580934)

“…Sludge dissolved organic carbon (DOC) decreased to 272 mg/L with a 65.2% reduction by <i>Mucor</i> sp. …”

Differentially expressed genes involved in neurogenesis and neuronal differentiation after injury in zebrafish spinal cord and validation of Sox2 expression by immunohistochemistry... by Subhra Prakash Hui (510710)

“…Red and green colors represent increased and decreased expression respectively. Scale bar = 50 µm (A–G and M–O), 20 µm (H–L).…”

DataSheet1_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.zip by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats by Michaela Lang (117542)

“…Riociguat (BAY 63–2521) is a stimulator of sGC that works both in synergy with and independently of NO to increase levels of cGMP. …”

Image4_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.TIF by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

Image3_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.JPEG by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

Image6_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.TIF by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

Image8_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.TIF by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

Image9_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.TIF by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

Image5_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.TIF by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

Image7_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.TIF by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

Image11_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.TIF by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”

Image10_SGLT2 inhibitors suppress epithelial–mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway.TIF by Ruixue Guo (6377939)

“…Additionally, SGLT2, IGF1R, phosphorylated PI3K, α-SMA, SNAI-1, and ZEB2 protein levels were increased in high glucose-stimulated human podocytes (HPC) and significantly decreased in dapagliflozin-treated (50 nM and 100 nM) or OSI-906-treated (inhibitor of IGF1R, 60 nM) groups. …”